Völp, Andreas
Schmitz, Jennifer
Bulitta, Michael
Raskopf, Esther
Acikel, Cengizhan
Mösges, Ralph
Article History
Received: 24 March 2022
Accepted: 15 November 2022
First Online: 21 November 2022
Competing interests
: AV, JS and MB report personal fees from Engelhard Arzneimittel GmbH & Co. KG, Niederdorfelden, Germany. ER and CA declare no competing interests. RM reports grants and personal fees from Engelhard, during the conduct of the study, personal fees from allergopharma, grants and personal fees from Allergy Therapeutics, grants and personal fees from Bencard, grants and personal fees from Leti, grants and personal fees from Lofarma, grants and personal fees from Stallergenes, grants from Optima, personal fees from Friulchem, grants and personal fees from Hexal, grants and personal fees from Klosterfrau, personal fees from FAES, personal fees from Meda, personal fees from Novartis, personal fees from UCB, grants and personal fees from BitopAG, grants from Hulka, grants from Ursapharm, personal fees and non-financial support from Menarini, personal fees from Mundipharma, personal fees from Pohl-Boskamp, grants from Inmunotek, personal fees from Hikma, personal fees from Sandoz, grants and personal fees from Lek, grants and personal fees from Cassella, personal fees from SanofiGenzyme, non-financial support from SmartPeakFlow, personal fees from Strathos, grants from Aimmune, outside the submitted work; and RM is the director and the owner of Clinical Research International Ltd. and of ClinCompetence Cologne GmbH, two contract research organizations focusing on upper airways diseases.